Hearing that a medication you depend on every day may not be safe can be deeply unsettling. That’s exactly what patients felt when news emerged that Teva Pharmaceuticals had recalled a blood pressure drug. The company identified a chemical impurity in several batches of prazosin hydrochloride—an impurity that could potentially increase cancer risk over long periods.
Across the country, patients were left wondering the same thing: what now? The recall does not mean the medication is immediately dangerous, but it raises concerns about how such contamination can occur in the first place.
What Happened and Why It Matters
In early October 2025, Teva Pharmaceuticals—a major generic drug manufacturer—voluntarily recalled hundreds of thousands of bottles of prazosin hydrochloride from pharmacies. The recall impacted the 1 mg, 2 mg, and 5 mg dosage strengths.
Testing detected an impurity known as N-nitroso prazosin, which belongs to a group of chemicals called nitrosamines. These substances are not new concerns; scientists have tracked them for years because they can form during manufacturing and may be linked to cancer after prolonged exposure.
The FDA categorized the recall as Class II, meaning the risk of serious harm is considered low. Still, the idea of a carcinogenic impurity in a daily medication understandably unsettled patients who rely on prazosin for blood pressure control.
